IMMUVANCE Trademark

Trademark Overview

On Tuesday, June 9, 2020, a trademark application was filed for IMMUVANCE with the United States Patent and Trademark Office. The USPTO has given the IMMUVANCE trademark a serial number of 88956377. The federal status of this trademark filing is ABANDONED - EXPRESS AFTER PUB as of Tuesday, February 16, 2021. This trademark is owned by CytoDyn Inc.. The IMMUVANCE trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:

therapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor

scientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor

providing health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and dis...
immuvance

General Information

Serial Number88956377
Word MarkIMMUVANCE
Filing DateTuesday, June 9, 2020
Status605 - ABANDONED - EXPRESS AFTER PUB
Status DateTuesday, February 16, 2021
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 8, 2020

Trademark Statements

Description of MarkThe mark consists of a representation of an abstracted antibody on a circular background shown adjacent to the term "IMMUVANCE" in stylized letters.
Goods and Servicestherapeutic preparations, namely, therapeutic preparations for the treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19, and therapeutic preparations for the prevention of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; therapeutic preparations, namely, antibodies for use in targeting the CCR5 cell receptor
Goods and Servicesscientific research consulting services, namely, scientific research consulting services in the field of immunology, and scientific research consulting services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services, and medical research services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; medical research services in the field of antibodies for use in targeting the CCR5 cell receptor
Goods and Servicesproviding health and medical information, and providing health and medical information in the nature of providing a website featuring information in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19; providing a website featuring medical information; providing a website featuring medical information in the field of antibodies for use in targeting the CCR5 cell receptor; medical analysis services, namely, medical analysis services in the field of antibodies for use in targeting the CCR5 cell receptor, and medical analysis services in the field of therapeutic agents, preparations and substances for the prevention and/or treatment of HIV, cancer, graft-versus-host disease, autoimmune diseases, nonalcoholic steatohepatitis, immune system related diseases and disorders, respiratory diseases and disorders, COVID-19

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code8 - Abandoned
Class Status DateTuesday, February 16, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code8 - Abandoned
Class Status DateTuesday, February 16, 2021
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code8 - Abandoned
Class Status DateTuesday, February 16, 2021
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameCytoDyn Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressVancouver, WA 98660
Party NameCytoDyn Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressVancouver, WA 98660

Trademark Events

Event DateEvent Description
Tuesday, February 16, 2021ABANDONMENT NOTICE E-MAILED - AFTER PUBLICATION
Tuesday, February 16, 2021ABANDONMENT - AFTER PUBLICATION
Tuesday, February 9, 2021TEAS EXPRESS ABANDONMENT RECEIVED
Monday, December 21, 2020EXTENSION OF TIME TO OPPOSE RECEIVED
Tuesday, December 8, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 8, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 18, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 5, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 28, 2020ASSIGNED TO EXAMINER
Tuesday, July 7, 2020NOTICE OF DESIGN SEARCH CODE E-MAILED
Monday, July 6, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, June 12, 2020NEW APPLICATION ENTERED IN TRAM

Related Keywords

immuvance diseases disorders medical services field therapeutic preparations immune related steatohepatitis